Kimberley A. Elting - 05 Jan 2023 Form 4 Insider Report for Orthofix Medical Inc. (OFIX)

Role
President, Global Orthopedics
Signature
/s/ Patrick Keran, attorney-in-fact
Issuer symbol
OFIX
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
4
Filing time
09 Jan 2023, 18:12:10 UTC
Previous filing
05 Jan 2023
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OFIX Common Stock Award $0 +35,129 +33% $0.000000 140,924 05 Jan 2023 Direct F1
transaction OFIX Common Stock Award $0 +11,534 +8.2% $0.000000 152,458 05 Jan 2023 Direct F2
transaction OFIX Common Stock Award $0 +12,229 +8% $0.000000 164,687 05 Jan 2023 Direct F3
transaction OFIX Common Stock Award $0 +20,492 +12% $0.000000 185,179 05 Jan 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OFIX Employee Stock Option (Right to Buy) Award $0 +84,566 $0.000000 84,566 05 Jan 2023 Common Stock 84,566 $20.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date.
F2 Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.
F3 Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.
F4 Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.
F5 The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first anniversary of the Grant Date and one-twelfth (1/12th) of the shares covered thereby on each of the 15-month, 18-month, 21-month, 24-month, 27-month, 30-month, 33-month and 36-month anniversaries of the Grant Date.